JMP Securities analyst Silvan Tuerkcan downgraded Intellia Therapeutics to Market Perform from Outperform.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NTLA:
- Intellia awarded innovation passport in UK for NTLA-2002
- Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema
- ZM, NTLA, or SQ: Which Cathie Wood ARKK Stock Is Most Appealing in 2023?
- Intellia Therapeutics highlights strategic priorities, milestones for 2023
- Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones